Erratum for Tehrani F, et al. "Value of Medical Therapy in Patients >80 Years of Age With Heart Failure and Preserved Ejection Fraction" Am J Cardiol 2009;103:829-833 (DOI:10.1016/j.amjcard.2008.11.047);Value of Medical Therapy in Patients >80 Years of Age With Heart Failure and Preserved Ejection Fraction

American Journal of Cardiology

Volumn 103, Issue 6, 2009, Pages 829-833

  Tehrani, Faramarz ^a   Phan, Anita ^a   Chien, Christopher V ^a   Morrissey, Ryan P ^a   Rafique, Asim M ^a   Schwarz, Ernst R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

AGED; ARTICLE; DRUG EFFECT; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL;

EID: 61749092896     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.04.054     Document Type: Erratum

References (14)

1. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
2. Fukuta H., Sane D.C., Brucks S., and Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
3. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
4. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
5. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., and Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
6. Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., and Taylor J. The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) Study. Eur Heart J 27 (2006) 2338-2345
7. Setaro J.F., Zaret B.L., Schulman D.S., Black H.R., and Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 66 (1990) 981-986
8. Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-Solal A., Dumitrascu D., Ferrari R., Lechat P., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
9. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
10. GISSI-HF Investigators, Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., and Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
11. Shah R., Wang Y., and Foody J.M. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients > or = 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 101 (2008) 217-222
12. Afilalo J., Duque G., Steele R., Jukema J.W., de Craen A.J., and Eisenberg M.J. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 51 (2008) 37-45
13. Wenger N.K., Lewis S.J., Herrington D.M., Bittner V., and Welty F.K. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 147 (2007) 1-9
14. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., Ryden L., Thygesen K., and Uretsky B.F. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999) 2312-2318